Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Cardiology
•
Preventive Cardiology
How do you decide between IL-1 inhibitors, azathioprine, and IVIG for steroid-dependent recurrent/incessant pericarditis?
Related Questions
How would you manage cardiac sarcoid with intolerance/contraindications to methotrexate, azathioprine, and mycophenolate/mycophenolic acid and that has proven refractory to adalimumab and infliximab as determined by PET?
For patients with hypertension who have normal filling pressures following right cardiac catheterization, can hypertension still be attributed to volume overload?
What are some general thoughts you have on the clinical utility and value of high sensitivity troponin in patients when there is little clinical evidence for acute MI or acute decompensated heart failure, and lack of evidence to support non-ischemic myocardial injury?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
How would you approach the risk-benefit ratio of systemic anticoagulation in certain clinical scenarios such as atrial fibrillation or LV thrombus when a patient's history is also notable for type B aortic dissection or other aortic pathology such as aortic ulceration?
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
What are some immunosuppression regimens to consider in a patient with refractory cardiac sarcoidosis?
Should CT coronary calcium score be avoided in dialysis patients in light of presumed high prevalence of CAC in this population?
What are some potential etiologies to consider for isolated, mildly elevated BNP levels with normal TTE findings in an asymptomatic, elderly patient?
How would you further risk stratify patients with systemic vasculitides and chest pain with atypical features?
